Attached files
| file | filename |
|---|---|
| EX-10.42 - AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT - AMGEN INC | amgn-ex1042amend1tolicense.htm |
| 10-Q - 10-Q - AMGEN INC | amgn-2017630x10q.htm |
| EX-31 - EXHIBIT 31 - AMGEN INC | amgn-ex31_2017630xq2.htm |
| EX-10.44 - COLLABORATION AGREEMENT - AMGEN INC | amgn-ex1044collaborationag.htm |
| EX-10.43 - AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT - AMGEN INC | amgn-ex1043amend2tonovarti.htm |
| EX-10.41 - EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT - AMGEN INC | amgn-ex1041amgenxnovartism.htm |
Exhibit 32
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
(i) | the accompanying Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
(ii) | information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: July 26, 2017 | /s/ ROBERT A. BRADWAY |
Robert A. Bradway | |
Chairman of the Board, | |
Chief Executive Officer and President | |
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
1
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
(i) | the accompanying Quarterly Report on Form 10-Q of the Company for the period ended June 30, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
(ii) | information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: July 26, 2017 | /s/ DAVID W. MELINE |
David W. Meline | |
Executive Vice President and Chief Financial Officer | |
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Amgen Inc. and will be retained by Amgen Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
2